Shattuck Labs, Inc. files for IPO.

The IPO of Shattuck Labs, Inc. (STTK) will take place on October 8, 2020. PMV Shattuck Labs, Inc. is an innovative clinical stage biotechnology company pioneering in the development of bilateral fusion proteins as a completely new class of biological medicine. The company develops drugs to treat cancer and improve the body's immune response against tumors.  Shattuck Labs has developed an ARC platform to overcome the limitations of existing bivalent antibodies.  ARC compounds combine checkpoint blockade and immune co-stimulation within a single therapeutic agent.

Listed underwriters of the IPO are Citigroup, Cowen, Evercore ISI and Needham & Company.